Novo Nordisk announced positive trial results for its obesity drug, amycretin, showing a 22% weight loss over 36 weeks. This positions it competitively against Eli Lilly's treatments. Despite a recent stock rise, Novo Nordisk's shares have underperformed over the past year. The company is also facing competition from Eli Lilly's oral treatments. Teljes cikk (Euronews.com)